Delivering an end-to-end industrialization roadmap for autologous cell therapy

Sponsor

Today’s autologous cell therapy footprint has been expanding over recent years and the recent commercialization of certain CAR T therapies has further ignited the autologous growth across the globe. With hundreds of products in the pre-clinical and clinical phases, the industry has improved in both a quantitative and qualitative way, but has also been exposed to numerous pain points that have created critical bottlenecks affecting the ability for a smooth transition from clinic to market. From overall product cost of goods (COGs) to supply chain constraints, there is a critical need to industrialize the end-to-end process to allow for these life saving therapies to be commercialized and available to the global markets.

During this webinar, our experts reveal an end-to-end industrialization roadmap for drug developers of autologous cell therapies. This roadmap includes the key technologies, such as the Cocoon platform, necessary to achieve reliable COGs and scalability of these personalized medicines, as well as the partnerships required to build a supply chain network that will deliver ‘just-in-time’ manufacturing to patients.

The specificities and challenges associated with autologous cell therapy manufacturing
Leveraging automation for scalability of autologous cell therapy manufacturing with the Cocoon platform
How to build a robust vein-to-vein network to achieve ‘just-in-time’ delivery of autologous cell therapies

Joe Garrity

Head of Autologous Cell Therapy Commercial Development, CGT, Lonza

Joe Garrity is the Head of Autologous Cell Therapy, Commercial Development at Lonza Cell and Gene Technologies where he works within their global Cell and Gene business unit. He works within the business leadership team to enable strategic development and growth of the autologous modality in Lonza CGT, as well as works with operations, development, and quality teams to streamline the clinical and commercial manufacturing services and offers provided by Lonza. Joe has an educational background in biochemistry and a professional background of nearly a decade within the cell and gene CDMO space that has covered positions within development, operations, and business functions.

Matthew Hewitt

Head, R&D and Clinical Development, Personalized Medicine, Lonza

Matthew Hewitt is currently the Head of Clinical Development for the Personalized Medicine (PerMed) Initiative within Lonza. The PerMed Initiative has a cell and gene therapy focus working to alleviate pain-points in commercializing cell therapies. One of Matt’s responsibilities is the Cocoon Platform, a closed, automated, scalable cell therapy manufacturing platform which relieves many cell therapy manufacturing difficulties. Prior to joining Lonza, Matt led the Tumor Immunology and Microenvironment program at Bellicum Pharmaceuticals which concentrated on improving cell therapy efficacy in solid tumors. Matt led the Immunology group at the University of Pennsylvania’s Gene Therapy Program under Dr. James Wilson managing numerous AAV gene therapy programs. Matt received his Ph.D. in Biophysics & Physiology from the University of Alabama at Birmingham and completed his post-doctoral fellowship at Johns Hopkins University.

Walter Bagni

Cell & Gene Technologies & Labelling CoE Lead, Lonza

Walter Bagni is the Cell & Gene Technologies & Labeling CoE Lead at Lonza. Lonza is a Swiss company with a strong focus on process development and contract manufacturing of therapeutic materials including small molecules, biologics, viruses and cells. Mr. Bagni brings an outstanding 20 years’ experience in the Pharma industry and Information Technology. This experience covers across all aspects of IT/OT technologies for Technical Operations of the Pharma Industry. For the past 5 years, his focus has shifted on identifying and enabling tools that are aimed at providing optimal solutions to answer the challenges that stem from the new developments in the Cell and Gene Technology sector.

Watch now